Summary

Other Scenarios:

Buyer: OSI Pharmaceuticals, Inc. (OSIP) Last Price: 45.16 Market Cap.: 2.58B
Target: Myriad Genetics, Inc. (MYGN) Last Price: 57.71 Market Cap.: 2.58B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 860
Biopharmaceuticals 373
Healthcare Services   142
Medical Devices 231

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 13)
  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  • PSN010 (Glucokinase Activators)
  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  • Novantrone (Mitoxantrone Hydrochloride)
Target (Total: 12)
  • MPC-0920 (Direct Thrombin Inhibitor)
  • Vivecon (Viral Maturation Inhibitor)
  • Flurizan (R-Flurbiprofen)
  • MPC-2130 (Apoptosis Inducer)
Buyer
  • Gelclair
Target
  • Myriad Genetic Laboratories
  • BRACAnalysis/BRACAnalysis Rearrangement Test
  • COLARIS
  • COLARIS AP

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 6)
  • Wyeth (WYE)
  • Gilead Sciences, Inc. (GILD)
  • ISIS Pharmaceuticals, Inc. (ISIS)
  • Enzon Pharmaceuticals, Inc. (ENZN)
Target (Total: 4)
  • Genetic Technologies Limited (ADR) (GENE)
  • EpiCept Corporation (EPCT)
  • University of Pennsylvania
  • University of Utah
Buyer (Total: 5)
  • Novartis AG (ADR) (NVS)
  • Genentech, Inc. (DNA)
  • Merck & Co., Inc. (MRK)
  • Eli Lilly & Co. (LLY)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 488 848
Revenue Per Employee 742,728.8 291,457.3
Total Revenue 90.7 61.8
Total Expenses 57.9 69.6
Other Revenue 0.0 0.0
Cost of Revenue 2.2 8.3
SG&A Expense 24.5 30.2
Research & Development 30.5 31.2
Other Operating Expense 0.0 0.0
Operating Income 32.9 -7.8
Unusual Income 0.0 0.0
LT Debt to Capital 73.99 0
Fwd P/E 21.26 -101.67
Fwd P/Rev 6.84 11.00
Book Value 110.8 353.3
Curr Portion of LTD/Cap Lease 137.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Oncology

Target

Focused (): Healthcare > Biopharmaceuticals

Business Description

Buyer

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI Pharmaceuticals, Inc. also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. In October 2007, Roche Holding Ltd. and OSI Pharmaceuticals, Inc. announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy.

Target

Myriad Genetics, Inc. is a biotechnology company focused on the development and marketing of therapeutic and molecular diagnostic products. As of June 30, 2007, the Company had four drug candidates in seven clinical trials, and a number of other drug candidates that are in late-stage preclinical development. Its major drug development programs include Flurizan for the treatment of Alzheimer?s disease, Azixa for the treatment of primary and metastatic brain tumors, MPC-2130 for the treatment of hematologic cancers, MPC-0920 for the treatment of thrombosis, and Vivecon for the treatment of acquired immune deficiency syndrome (AIDS). The Company?s revenues, for the fiscal year ended June 30, 2007, consisted primarily of sales of molecular diagnostic products (92%) and research payments (8%). Its commercial molecular diagnostic products include BRACAnalysis, COLARIS, COLARIS AP and MELARIS. On April 10, 2008, the Company acquired NaturNorth Technologies, LLC.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 97.27 85.45
Operating Margin % 31.32 -19.03
Quick Ratio 2.28 6.53
Current Ratio 2.54 6.72
Coverage Ratio 0.04 -0.36
Total Assets 706.8 391.0
Return on Equity % 103.45 -7.22
Return on Assets % 16.21 -6.52
Cash+ ST Inv. Per Share 6.75 4.59
Total Debt 452.0 0.0
Total Debt to Equity % 408.12 0
Total Debt to Tangible Equity % 766.75 0
Debt to Asset % 63.95 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Healthcare Services  
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
  
Medical Devices
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MPC-0920 (Direct Thrombin Inhibitor)
  
Endocrinology/Metabolism  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  • PSN010 (Glucokinase Activators)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  
Immunology
Autoimmune Disorders  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths an enzyme that inhibits the proliferation of cells.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Vivecon (Viral Maturation Inhibitor)
  
Infectious Diseases  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Target Products:

  • Vivecon (Viral Maturation Inhibitor)
  
Neurology
Neurological Disorders  
Alzheimer`s Disease  
Gamma Secretase Inhibitors
Therapeutics that treat Alzheimer's Disease by selectively lowering levels of Amyloid beta 42, a toxic peptide to neural cells.

Target Products:

  • Flurizan (R-Flurbiprofen)
  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting a key enzyme involved with cell division.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Oncology
Digestive System  
Colon Cancer/Colorectal Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage colorectal cancer by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)
  
Pancreatic Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Myeloid  
Acute  
Erythroleukemic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Monocytic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myeloblastic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myelogenous (AML)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Promyelocytic (APL)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  • OSI-930 (c-kit/VEGFR-2 Inhibitor)
  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)
  • OSI-906 (Insulin-Like Growth Factor-1 Receptor Inhibitor)
  • CP-868,596 (Platelet-Derived Growth Factor Receptor Inhibitor)
  • Tarceva (Erlotinib)
  • OSI632/Formerly CP 547,632 (VEGFR Inhibitor)

Target Products:

  • MPC-2130 (Apoptosis Inducer)
  • Azixa/Formely MPC-6827 (Tubulin Inhibitor)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • OSI-027 (mTOR Inhibitor)

Target Products:

  • MPC-3100 (Heat Shock Protein 90 Inhibitor)
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
EGFR-TK Inhibitors/Monoclonal Antibodies
Therapeutics that treat lung cancer by blocking the tyrosine kinase enzyme and by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)
  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.

Buyer Products:

  • Tarceva (Erlotinib)
  
Urology  
Ovarian Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage ovarian cancers by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)
  
Prostate Cancer  
Palliative Agents  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.

Buyer Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Weight Management  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • PSN602 (Serotonin/Norepinephrine Reuptake Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  
Healthcare Services  
Patient Care  
Ambulatory/Outpatient  
Diagnostic  
Laboratory  
Specialized
Specialized laboratory testing services involving highly specialized equipment, personnel, and procedures.

Target Products:

  • Myriad Genetic Laboratories
  
Medical Devices
Clinical Diagnostics  
Chemistry  
Reagents  
Test Kits  
Genetic Analysis  
Cancers  
Breast Cancer
A test designed to determine pre-disposition to breast cancer.

Target Products:

  • BRACAnalysis/BRACAnalysis Rearrangement Test
  
Colorectal Cancer (Colon Cancer)
A test designed to determine pre-disposition to colorectal cancer.

Target Products:

  • COLARIS
  • COLARIS AP
  
Melanoma (Skin Cancer)
Test designed to determine pre-disposition to melanoma.

Target Products:

  • MELARIS
  
Ovarian Cancer
Test designed to determine pre-disposition to ovarian cancer.

Target Products:

  • BRACAnalysis/BRACAnalysis Rearrangement Test
  
Pancreatic Cancer
Test designed to determine pre-disposition to pancreatic cancer.

Target Products:

  • MELARIS
  
Uterine Cancer
Test designed to determine pre-disposition to uterine cancer.

Target Products:

  • COLARIS
  
Pharmacogenetic
Test kits designed to determine individuals' reaction to specific medications based on their specific genes.

Target Products:

  • TheraGuide 5-FU
  
Medical Supplies  
Treatment  
Wound Management/First Aid  
Drainage/Hydration
Medical devices designed to irrigate, moisturize and remove excess fluids from wounds and wound surface.

Buyer Products:

  • Gelclair
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Johnson & Johnson n/a 186,733.396 16.10 15.01 3.00 2.94 11.53
Roche Holding Ltd. (ADR) n/a 152,673.567 16.04 16.65 3.39 3.51 4.87
Novartis AG (ADR) n/a 129,180.271 10.68 15.73 3.25 3.22 4.71
Pfizer Inc. n/a 120,488.157 15.99 7.67 2.52 2.54 4.64
Sanofi-Aventis SA (ADR) n/a 95,624.864 12.29 8.62 2.12 2.25 n/a
Abbott Laboratories n/a 87,088.194 22.64 17.76 3.26 3.03 40.30
Genentech, Inc. n/a 81,706.852 26.82 24.73 6.84 6.32 7.85
AstraZeneca plc (ADR) n/a 66,659.787 12.04 10.24 2.20 2.17 n/a
Wyeth n/a 64,400.224 14.13 14.15 2.83 2.86 4.36
Amgen, Inc. n/a 55,545.270 17.41 12.83 3.78 3.90 12.43
Eli Lilly & Co. n/a 54,199.599 15.45 12.25 2.82 2.70 4.32
Bristol Myers Squibb Co. n/a 41,809.109 19.57 12.87 2.07 2.01 9.77
Millennium Pharmaceuticals, Inc. n/a 8,172.386 224.96 n/a 14.69 n/a n/a
ImClone Systems Incorporated n/a 3,496.246 n/a 33.82 5.71 5.06 4.41
Onyx Pharmaceuticals, Inc. n/a 2,209.779 n/a 51.01 n/a 15.95 4.89
Regeneron Pharmaceuticals, Inc. n/a 1,192.921 n/a -11.04 7.20 6.52 2.59
Arena Pharmaceuticals, Inc. n/a 443.064 n/a -1.96 26.01 31.36 1.34
Enzon Pharmaceuticals, Inc. n/a 323.867 3.71 -19.16 1.68 1.67 n/a
MannKind Corporation n/a 288.049 n/a -0.97 14,200.00 561.90 0.97
XOMA Limited n/a 238.114 n/a -6.00 2.83 3.18 n/a
Target
  Clinical Data, Inc. n/a 294.902 n/a n/a 8.67 n/a 4.69
Verenium Corporation n/a 69.375 n/a -1.10 1.38 1.31 n/a
EPIX Pharmaceuticals, Inc. n/a 62.036 n/a -1.21 4.03 2.35 n/a
Athersys, Inc. n/a 49.213 n/a -2.77 15.51 15.38 1.13
Panacos Pharmaceuticals, Inc. n/a 29.988 n/a -0.83 155.56 63.00 1.40

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Wyeth n/a 64,400.224 14.13 14.15 2.83 2.86 4.36
Gilead Sciences, Inc. n/a 49,536.606 29.07 26.76 11.11 9.78 14.88
ISIS Pharmaceuticals, Inc. n/a 1,412.634 n/a -68.38 15.96 14.59 79.74
Enzon Pharmaceuticals, Inc. n/a 323.867 3.71 -19.16 1.68 1.67 n/a
Nektar Therapeutics n/a 320.635 n/a -3.47 1.54 3.65 3.38
Cadus Corporation n/a 20.768 267.80 n/a 207.89 n/a 0.81
Target
  Genetic Technologies Limited (ADR) n/a 31.045 n/a n/a 2.66 n/a 2.80
EpiCept Corporation n/a 15.419 n/a n/a 70.69 n/a n/a
University of Pennsylvania n/a n/a n/a n/a n/a n/a n/a
University of Utah n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Novartis AG (ADR) n/a 129,180.271 10.68 15.73 3.25 3.22 4.71
Genentech, Inc. n/a 81,706.852 26.82 24.73 6.84 6.32 7.85
Merck & Co., Inc. n/a 78,884.905 16.19 11.18 3.25 3.26 4.53
Eli Lilly & Co. n/a 54,199.599 15.45 12.25 2.82 2.70 4.32
Bristol Myers Squibb Co. n/a 41,809.109 19.57 12.87 2.07 2.01 9.77

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 152,673.567 16.04 16.65 3.39 3.51 4.87
Novartis AG (ADR) n/a 129,180.271 10.68 15.73 3.25 3.22 4.71
Pfizer Inc. n/a 120,488.157 15.99 7.67 2.52 2.54 4.64
Abbott Laboratories n/a 87,088.194 22.64 17.76 3.26 3.03 40.30
Genentech, Inc. n/a 81,706.852 26.82 24.73 6.84 6.32 7.85
Merck & Co., Inc. n/a 78,884.905 16.19 11.18 3.25 3.26 4.53
Wyeth n/a 64,400.224 14.13 14.15 2.83 2.86 4.36
Eli Lilly & Co. n/a 54,199.599 15.45 12.25 2.82 2.70 4.32
Gilead Sciences, Inc. n/a 49,536.606 29.07 26.76 11.11 9.78 14.88
Bristol Myers Squibb Co. n/a 41,809.109 19.57 12.87 2.07 2.01 9.77
ISIS Pharmaceuticals, Inc. n/a 1,412.634 n/a -68.38 15.96 14.59 79.74
Enzon Pharmaceuticals, Inc. n/a 323.867 3.71 -19.16 1.68 1.67 n/a
Nektar Therapeutics n/a 320.635 n/a -3.47 1.54 3.65 3.38
Transgenomic, Inc. n/a 39.844 n/a n/a 1.65 n/a 3.19
Cadus Corporation n/a 20.768 267.80 n/a 207.89 n/a 0.81
Catalent Pharma Solutions n/a n/a n/a n/a n/a n/a n/a
Schwarz Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a
Dipharma Francis Srl n/a n/a n/a n/a n/a n/a n/a
AVEO Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  AstraZeneca plc (ADR) n/a 66,659.787 12.04 10.24 2.20 2.17 n/a
Genetic Technologies Limited (ADR) n/a 31.045 n/a n/a 2.66 n/a 2.80
EpiCept Corporation n/a 15.419 n/a n/a 70.69 n/a n/a
University of Utah n/a n/a n/a n/a n/a n/a n/a
H. Lundbeck A/S n/a n/a n/a n/a n/a n/a n/a
University of Pennsylvania n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 354.3 212.3 566.5
Other Revenue 0.0 0.0 0.0
Total Revenue 354.3 212.3 566.5
Cost of Revenue 9.7 30.9 40.6
SG&A Expense 98.6 111.1 209.7
Depreciation & Amortization 2.0 0.0 2.0
Research & Development 123.5 110.7 234.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 9.7 0.0 9.7
Total Expenses 243.3 252.7 496.0
Operating Income 111.0 -40.4 70.6
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 4.9 14.6 19.5
Other, Net 1.7 0.3 2.0
Income Before Taxes 117.6 -25.5 92.1
Income Taxes 3.0 0.0 3.0
Income After Taxes 114.6 -25.5 89.1
Net Income - Excl. Xord. Items 114.6 -25.5 89.1
Discontinued Operations -25.7 0.0 -25.7
Net Income - Incl. Xord. Items 88.9 -25.5 63.4
Income Avail. to Common 88.9 -25.5 63.4
Share Items
Basic Avg. Shares Outstanding 57.1 44.4 101.6
Basic EPS - Excl. Xord. Items 2.01 n/a 0.88
Basic EPS - Incl. Xord. Items 1.56 n/a 0.62
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 64.7 44.4 109.1
F.D. EPS - Excl. Xord. Items 1.77 n/a 0.82
F.D. EPS - Incl. Xord. Items 1.38 n/a 0.58
Balance Sheet
Assets
Cash and Equivalents 313.4 142.4 455.8
ST Investments 122.9 61.8 184.7
Accounts Receivable 89.1 41.7 130.8
Inventory 20.7 0.0 20.7
Prepayments and Advances 9.4 7.0 16.4
Other Current Assets 30.1 0.0 30.1
Current Assets 585.6 252.9 838.5
PPE 0.0 72.3 72.3
Accum D&A 0.0 -44.2 -44.2
PPE, Net 45.3 28.1 73.4
Goodwill & Intangibles 51.8 0.0 51.8
Long Term Investments 0.0 106.3 106.3
Other Assets 0.0 0.0 0.0
Other LT Assets 24.1 3.6 27.7
Total Assets 706.8 391.0 1,097.8
Liabilities
Accounts Payable 0.0 12.0 12.0
Payable/Accrued 43.4 0.0 43.4
Accrued Expenses 0.0 23.6 23.6
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 137.0 0.0 137.0
Other (Current) Liabilities 50.0 2.1 52.1
Current Liab. 230.4 37.7 268.1
LT Debt 315.0 0.0 315.0
Total LT Debt 315.0 0.0 315.0
Other LT Liab. 50.6 0.0 50.6
Total Liabilities 596.0 37.7 633.7
Shareholders Equity
Common Stock 0.6 0.4 1.0
Additional Paid in Capital 1,665.9 621.7 2,287.5
Retained Earnings -1,458.4 -270.1 -1,728.5
Treasure Stock -102.2 0.0 -102.2
Other Equity 5.0 1.3 6.2
Total Equity 110.8 353.3 464.0
Total Liab. & Equity 706.8 391.0 1,097.8
Shares Outstanding 57.0 44.6 101.7
Cash Flow
Operating Cash Flow
CF Net Income 69.3 -25.5 43.8
CF Depreciation 7.7 8.5 16.2
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 25.6 23.0 48.5
Change in Working Capital -28.2 -13.8 -42.0
Total Cash From Operating Activities 74.3 -7.8 66.5
Investing Cash Flow (not calculated)
Capital Expenditures -21.3 -12.4 -33.7
Other Investing Cash Flows 31.8 -57.3 -25.5
Total Cash From Investing Activities 10.5 -69.7 -59.3
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -44.9 25.1 -19.8
Purchase and Retirement of Debt 200.0 0.0 200.0
Other Financing Cash Flow -21.4 0.0 -21.4
Total Cash From Financing Activities 133.8 25.1 158.9
Exchange Rate Effects -0.2 0.0 -0.2
Net Change in Cash 218.3 -52.5 165.9
Cash Taxes Paid 0.1 0.0 0.1
Cash Interest Paid 6.0 0.0 6.0